- Home
- CVKD vs ENLV Comparison
CVKD vs ENLV Comparison
Compare CVKD & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- ENLV
- Stock Information
- Founded
- CVKD 2022
- ENLV 2005
- Country
- CVKD United States
- ENLV Israel
- Employees
- CVKD N/A
- ENLV N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- ENLV Health Care
- Exchange
- CVKD Nasdaq
- ENLV Nasdaq
- Market Cap
- CVKD 29.5M
- ENLV 23.7M
- IPO Year
- CVKD 2023
- ENLV 1995
- Fundamental
- Price
- CVKD $12.32
- ENLV $1.09
- Analyst Decision
- CVKD Strong Buy
- ENLV Strong Buy
- Analyst Count
- CVKD 1
- ENLV 2
- Target Price
- CVKD $32.00
- ENLV $10.00
- AVG Volume (30 Days)
- CVKD 20.0K
- ENLV 58.0K
- Earning Date
- CVKD 08-06-2025
- ENLV 05-30-2025
- Dividend Yield
- CVKD N/A
- ENLV N/A
- EPS Growth
- CVKD N/A
- ENLV N/A
- EPS
- CVKD N/A
- ENLV N/A
- Revenue
- CVKD N/A
- ENLV N/A
- Revenue This Year
- CVKD N/A
- ENLV N/A
- Revenue Next Year
- CVKD N/A
- ENLV N/A
- P/E Ratio
- CVKD N/A
- ENLV N/A
- Revenue Growth
- CVKD N/A
- ENLV N/A
- 52 Week Low
- CVKD $5.70
- ENLV $0.81
- 52 Week High
- CVKD $22.90
- ENLV $1.76
- Technical
- Relative Strength Index (RSI)
- CVKD 38.54
- ENLV 65.75
- Support Level
- CVKD $13.12
- ENLV $0.90
- Resistance Level
- CVKD $15.99
- ENLV $1.07
- Average True Range (ATR)
- CVKD 0.76
- ENLV 0.06
- MACD
- CVKD -0.08
- ENLV 0.02
- Stochastic Oscillator
- CVKD 6.45
- ENLV 70.37
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.